Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 57 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Meta-analysis identified 44 CpGs and 44 differentially methylated regions consistently associated with time to dementia in both cohorts. Our integrative analysis identified early processes in dementia, such as immune responses and metabolic dysfunction. Furthermore, we developed a methylation-based risk score, which successfully predicted future cognitive decline in an independent validation set, even after accounting for age, sex, apolipoprotein E ε4, years of education, baseline diagnosis, and baseline Mini-Mental State Examination score. DNAm offers a promising source as a biomarker for dementia risk assessment. HIGHLIGHTS: Blood DNA methylation (DNAm) differences at individual CpGs and differentially methylated regions are significantly associated with incident dementia. Pathway analysis revealed DNAm differences associated with incident dementia are significantly enriched in biological pathways involved in immune responses and metabolic processes. Out-of-sample validation analysis demonstrated that a methylation-based risk score successfully predicted future cognitive decline in an independent dataset, even after accounting for age, sex, apolipoprotein E ε4, years of education, baseline diagnosis, and baseline Mini-Mental State Examination score.

What this study adds

Evidence grade: High

This is a pooled review. A blood DNA methylation signature was consistently associated with time to dementia across two cohorts, and a methylation-based risk score predicted future cognitive decline in an independent validation set even after accounting for other factors. The authors describe DNA methylation as a promising source for dementia risk assessment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zhang, W., Young, J. I., Gomez, L., Schmidt, M. A., Lukacsovich, D., Kunkle, B. W., et al. (2025). Blood DNA methylation signature for incident dementia: Evidence from longitudinal cohorts. Alzheimer s & Dementia. https://doi.org/10.1002/alz.14496

Vancouver

Zhang W, Young JI, Gomez L, Schmidt MA, Lukacsovich D, Kunkle BW, et al. Blood DNA methylation signature for incident dementia: Evidence from longitudinal cohorts. Alzheimer s & Dementia. 2025. doi:10.1002/alz.14496. PMID: 40133250.

BibTeX

@article{zhang2025-40133250,
  author  = {Zhang, Wei and Young, Juan I. and Gomez, Lissette and Schmidt, Michael A. and Lukacsovich, David and Kunkle, Brian W. and Chen, X. Steven and Martin, Eden R. and others},
  title   = {{Blood DNA methylation signature for incident dementia: Evidence from longitudinal cohorts}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.14496},
  pmid    = {40133250},
  url     = {https://doi.org/10.1002/alz.14496}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

A blood DNA methylation signature was consistently associated with time to dementia across two cohorts, and a methylation-based risk score predicted future cognitive decline in an independent validation set even after accounting for other factors. The authors describe DNA methylation as a promising source for dementia risk assessment.

Study details

How this study scored 57/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 57 of 100.57 of 100 points earned43 not earned

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.3 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 8.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Lily Wang: h-index 9 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Miami: institution h-index 998 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40133250)
Free to read 2 / 2 Free to read
Total 57 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in How common it is from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on How common it is

See all studies in How common it is →